Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551713 | 0.83 | CNR1 (0.39) | CNR1CNR2HSD11B1MAPT | |
| SCHEMBL3547208 | 0.83 | ALDH1A1 (0.40) | CNR1CNR2TP53MDM2 | |
| SCHEMBL3546576 | 0.82 | P2RX7 (0.37) | CNR1CNR2SHMT1SHMT2TP53 | |
| SCHEMBL3553263 | 0.82 | ALDH1A1 (0.37) | CNR1CNR2SHMT1SHMT2TP53 | |
| SCHEMBL3549630 | 0.81 | HSD11B1 (0.35) | CNR1CNR2SHMT1SHMT2HSD11B1 | |
| SCHEMBL3552196 | 0.79 | HSD11B1 (0.35) | CNR1CNR2SHMT1SHMT2HSD11B1 | |
| SCHEMBL3555703 | 0.78 | ALDH1A1 (0.38) | CNR1CNR2TP53MDM2MAPT | |
| SCHEMBL3550717 | 0.77 | MAPT (0.44) | CNR1CNR2TP53MDM2MAPT | |
| SCHEMBL5328457 | 0.77 | HSD11B1 (0.43) | HSD11B1 | |
| SCHEMBL3552068 | 0.76 | CNR1 (0.41) | CNR1CNR2TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674821-B2 | N-[(4,5-diphenyl-3-alkyl-2-thienyl)methyl]amine [amide, sulfonamide, carbamate and urea) derivatives as cannabinoid CB1 receptor antagonists | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | claimed |
| US-20070270470-A1 | N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | claimed |
| EP-1833812-A1 | N-[(4, 5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL]AMINE (AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2007-09-19 | — | — | EP | claimed |
| WO-2006070106-A1 | N-[(4, 5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | WO | claimed |
| US-7674821-B2 | N-[(4,5-diphenyl-3-alkyl-2-thienyl)methyl]amine [amide, sulfonamide, carbamate and urea) derivatives as cannabinoid CB1 receptor antagonists | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20070270470-A1 | N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
| EP-1833812-A1 | N-[(4, 5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL]AMINE (AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006070106-A1 | N-[(4, 5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270470-A1 | N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL)METHYL]AMINE [AMIDE, SULFONAMIDE, CARBAMATE AND UREA) DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | CNR1, CNR2, UTS2R | CNR1 1/4885CNR2 2/4885SHMT1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.